Shanghai Raas Blood Products Co.Ltd(002252) announced on December 27 that from December 13 to 15, 2021, the audit and inspection center of Henan food and Drug Administration conducted compliance inspection on the resumption of production of human immunoglobulin for intravenous injection in Zhengzhou. Recently, Zhengzhou Laishi has completed the rectification of the general defects proposed by the on-site inspection, and the production line of Zhengzhou Laishi intravenous human immunoglobulin can officially resume production. So far, Zhengzhou Laishi human serum albumin and intravenous human immunoglobulin can be put into production normally. In view of the small proportion of the plasma collection volume of the two single plasma collection stations under Zhengzhou Laishi in the total plasma collection volume of the company, the resumption of production by intravenous injection of human immunoglobulin will not have an important impact on the operating performance of the company in that year.
(interface News)
